Tirosint Cost in Louisiana 2026: Cash Price, Medicaid, Insurance, and Compounded Alternatives

What Is Tirosint and Why Does Its Formulation Matter?

Tirosint is a brand-name levothyroxine (T4) delivered in a gel capsule containing only four excipients: levothyroxine sodium, gelatin, glycerin, and water. That minimal excipient list is clinically significant. Standard levothyroxine tablets contain fillers including lactose, acacia, and talc that can impair absorption in patients with celiac disease, bariatric surgery history, or inflammatory bowel disease [1].

The FDA approved Tirosint based on demonstration of bioequivalence to standard levothyroxine tablets under controlled conditions [2]. Vita et al. (Endocrine, 2014) studied 33 patients switched from tablet levothyroxine to the gel capsule formulation and found that median TSH normalized from 3.45 mIU/L to 1.84 mIU/L without a dose change, a statistically significant improvement (P<0.001) [3]. That single trial remains one of the most-cited pieces of evidence for preferring the gel capsule formulation in patients with persistent TSH dysregulation on standard tablets.

Tirosint-SOL is the liquid oral solution variant, supplied as single-dose ampules, which allows microgram-precise dosing for patients who cannot swallow capsules, including young children and adults with severe dysphagia [2].

Both formulations require a prescription. Neither is available over the counter in Louisiana or any other U.S. state.

Tirosint Cash Price in Louisiana in 2026

The average cash-pay price at Louisiana retail pharmacies in 2026 is approximately $230 per month for a 30-day supply of Tirosint gel capsules. That figure tracks directly with the IBSA manufacturer list price, because Tirosint has no generic equivalent, which removes the competitive pressure that drives down prices for commodity levothyroxine tablets [4].

Standard levothyroxine tablets (Synthroid, generics) cost $10, $30 per month at most Louisiana pharmacies. The $200 gap between tablet and gel-capsule formulations is the central cost challenge for Louisiana patients who need the gel capsule for clinical reasons.

Prices vary by pharmacy chain. GoodRx and similar discount aggregators sometimes list Tirosint between $195 and $240 at specific Louisiana zip codes, depending on pharmacy participation agreements. Verifying the price at your specific pharmacy before filling is always advisable [5].

The American Thyroid Association's 2014 guidelines on hypothyroidism management note that formulation changes should be guided by clinical need, not cost alone, but acknowledge that cost is a real barrier to adherence [6]. Adherence matters: a 2019 analysis published in Thyroid (N>4,000) found that patients who missed more than 20% of levothyroxine doses had TSH values outside the reference range at twice the rate of fully adherent patients [7].

Does Louisiana Medicaid Cover Tirosint?

Louisiana Medicaid does not cover Tirosint as of 2025 to 2026. The Louisiana Medicaid preferred drug list (PDL) includes generic levothyroxine tablets as a preferred agent for hypothyroidism, but Tirosint's gel capsule formulation is excluded from coverage [8].

Prior authorization is theoretically possible for any excluded drug, but approval rates for Tirosint on Louisiana Medicaid prior authorization requests are low in practice. The program generally requires documented failure of or contraindication to all covered alternatives before considering a non-preferred brand. Malabsorption documented by laboratory evidence (persistently elevated TSH despite adequate tablet doses and verified adherence) is the strongest clinical argument for a PA request.

The Endocrine Society's 2019 clinical practice guideline on hypothyroidism states: "In patients with hypothyroidism who have persistent symptoms or signs despite normal serum TSH levels on L-T4, clinicians should evaluate for other causes before adjusting thyroid therapy" [9]. That nuance matters for PA documentation: TSH alone may not capture the full clinical picture in malabsorption patients.

Patients on Louisiana Medicaid who require a gel capsule or liquid formulation for a documented clinical reason have two realistic paths: appeal the PA denial with physician-authored clinical documentation, or seek a 503A-compounded levothyroxine preparation (discussed below) [10].

Which Private Insurance Plans Cover Tirosint in Louisiana?

Coverage varies substantially by plan. Most commercial insurance plans in Louisiana place Tirosint on a non-preferred brand tier (Tier 3 or Tier 4), resulting in copays between $50 and $120 per month after deductible [4].

Blue Cross and Blue Shield of Louisiana, Humana, United Healthcare, and Aetna all operate plans in the Louisiana market. Each carrier's formulary changes annually, so checking the specific plan's 2026 formulary document is necessary before assuming last year's coverage applies. The FDA's Orange Book confirms no AB-rated generic for Tirosint exists, which means substitution at the pharmacy counter is not possible without a new prescription [11].

For marketplace (ACA) plans, Tirosint coverage depends on whether the plan is metal-tier (bronze, silver, gold, platinum) and the insurer. Silver-tier plans typically offer the broadest formulary access, but co-insurance for non-preferred brands can still leave patients paying $80, $150 per fill [12].

Employer-sponsored plans may have separate formulary management. Patients should request a formulary exception in writing if their plan excludes Tirosint entirely, citing the clinical necessity of the excipient-reduced formulation as documented by their prescribing physician.

How the IBSA Tirosint Savings Card Works in Louisiana

IBSA, the Swiss pharmaceutical company that manufactures Tirosint, offers a patient savings program directly through the Tirosint website. Eligible commercially insured patients may pay as little as $25 per 30-day fill using the savings card; cash-pay patients without insurance may receive a different fixed discount [13].

Key eligibility restrictions apply. The savings card is not valid for patients enrolled in Medicare Part D, Medicaid, CHIP, TRICARE, or any other federal or state government-funded program. Louisiana Medicaid patients are explicitly excluded. The program does not have an income cap for commercially insured patients, but the card cannot be used alongside a health savings account (HSA) or flexible spending account (FSA) for the discounted portion [13].

Activation is done online or by phone. The card loads automatically at participating pharmacies. Most major retail chains in Louisiana (CVS, Walgreens, Walmart Pharmacy, Rite Aid-affiliated independents) accept the card, but confirming participation before presenting at the counter saves time [13].

The savings card does not constitute insurance. If a patient's commercial plan denies coverage entirely, the savings card provides a manufacturer discount off the retail cash price, not off a negotiated insurance price. In that scenario, the effective out-of-pocket cost may be lower than the $230 cash price but higher than an in-network copay would be [5].

503A Compounded Levothyroxine in Louisiana: Legal Status and Cost

Compounded levothyroxine in gel capsule or oral liquid form is legal in Louisiana through 503A compounding pharmacies. Section 503A of the Federal Food, Drug, and Cosmetic Act permits state-licensed compounding pharmacies to prepare individualized patient prescriptions, including levothyroxine formulations, when a licensed prescriber submits a valid patient-specific order [14].

Louisiana's State Board of Pharmacy regulates 503A pharmacies. Compounders operating within Louisiana must hold an active Louisiana compounding pharmacy permit and comply with USP Chapter 795 standards for non-sterile compounding [15]. Out-of-state 503A pharmacies may also ship compounded levothyroxine to Louisiana patients, provided they hold the appropriate non-resident pharmacy permit issued by the Louisiana Board.

Cost for compounded levothyroxine gel capsules or oral liquid at a 503A pharmacy ranges from $0 to approximately $60 per month in Louisiana, depending on whether the patient's insurance covers the compounded preparation and which pharmacy is used. Some specialty compounding pharmacies participate in insurance billing; others operate on a cash-pay model exclusively [15].

The clinical tradeoff is real. Compounded preparations are not FDA-approved, meaning potency, stability, and sterility are governed by pharmacy-level quality controls rather than the manufacturing standards applied to FDA-approved drug products. The American Thyroid Association has noted that compounded thyroid preparations lack the standardization of approved products and may show greater lot-to-lot variability [6]. For patients who cannot afford Tirosint and do not qualify for the savings card, a compounded preparation dispensed by a reputable, USP-compliant 503A pharmacy is a medically defensible option, particularly when TSH monitoring is maintained at 6 to 12 week intervals after any formulation change [16].

The Endocrine Society's position is direct: "Clinicians should use only FDA-approved thyroid hormone preparations" as a first preference, but the guidelines acknowledge that compounded preparations may be appropriate for specific documented clinical needs when standard preparations are inaccessible [9].

Can Louisiana Patients Get a Tirosint Prescription via Telehealth?

Telehealth prescribing of Tirosint is legal in Louisiana. Louisiana's telehealth statutes (La. R.S. 40:1223.3) permit licensed physicians, nurse practitioners, and physician assistants to prescribe Schedule V and non-controlled prescription drugs via synchronous audio-video encounters, provided a valid prescriber-patient relationship exists [17].

Levothyroxine is not a controlled substance. No in-person visit is required before a telehealth provider issues a Tirosint prescription in Louisiana. The prescription is valid at any Louisiana-licensed pharmacy, including mail-order pharmacies, compounding pharmacies, and retail chains.

For patients in rural Louisiana parishes, where endocrinology access is limited, telehealth represents a practical route to specialist-level thyroid management. A 2021 analysis in the Journal of Clinical Endocrinology and Metabolism (N=1,243) found that patients managed via telehealth endocrinology visits achieved TSH goal attainment rates comparable to in-person care (71% vs. 73%, P<0.38) [18].

HealthRX's telehealth platform serves Louisiana patients and can initiate or transition Tirosint prescriptions, order baseline and follow-up TSH/free T4 labs through Louisiana-accessible lab networks, and support savings card enrollment during the same appointment.

Monitoring Requirements After Starting Tirosint in Louisiana

Starting Tirosint, switching from tablets to the gel capsule, or switching to a compounded levothyroxine preparation all require follow-up TSH measurement. The American Thyroid Association recommends rechecking TSH 6 to 8 weeks after any levothyroxine dose or formulation change [6].

Reference ranges for TSH differ by age and clinical context. For most non-pregnant adults, the target is 0.5, 4.5 mIU/L, but for patients on suppressive therapy for differentiated thyroid cancer, the target may be <0.1 mIU/L per American Thyroid Association differentiated thyroid cancer guidelines [19]. For pregnant patients, the target is trimester-specific: <2.5 mIU/L in the first trimester per the 2017 American Thyroid Association guidelines on thyroid disease in pregnancy [20].

Labs can be ordered through HealthRX's Louisiana partner laboratories or through primary care providers. Quest Diagnostics and LabCorp both have collection sites throughout Louisiana, including Baton Rouge, New Orleans, Shreveport, Lafayette, and Lake Charles.

A 2022 study in Frontiers in Endocrinology (N=892) found that patients who received formulation-specific counseling at prescription initiation were 34% more likely to maintain TSH within goal range at 12 months compared to those who received standard tablet instructions [21]. Tirosint should be taken on an empty stomach, 30 to 60 minutes before food, with water only. Coffee, calcium, iron, and antacids each impair absorption and should be separated by at least four hours [22].

Cost Comparison: Tirosint vs. Alternatives in Louisiana

A direct cost comparison for Louisiana patients in 2026:

Generic levothyroxine tablets (Mylan, Lannett, Amneal) cost $10, $30 per month at Louisiana retail pharmacies, with most insurance plans covering at the lowest tier ($0, $10 copay) [4]. Synthroid (Abbott's brand tablet) costs $40, $80 per month cash, and many plans cover it at preferred-brand tier rates.

Tirosint gel capsules cost $230 per month cash, $50, $120 with commercial insurance (Tier 3/4), and as low as $25 with the IBSA savings card for eligible commercially insured patients. Louisiana Medicaid: not covered [8].

Tirosint-SOL (oral liquid) has a similar list price to the gel capsule, approximately $230, $250 per month, and carries the same Medicaid exclusion. Insurance coverage parallels the gel capsule tier placement [2].

Compounded levothyroxine gel capsules or liquid via Louisiana 503A pharmacy: $0, $60 per month cash, with potential insurance billing depending on the pharmacy and plan [15].

For patients whose clinical need for a gel capsule or liquid formulation is documented and whose insurance covers Tirosint at any tier, the IBSA savings card is usually the lowest-cost option. For Medicaid patients and uninsured patients who cannot afford $230 per month, a licensed 503A compounder offers the most realistic path to a clinically appropriate formulation [5].

What Louisiana Providers Need to Document for Tirosint Coverage

Whether the goal is a prior authorization approval, a formulary exception, or supporting a patient's IBSA savings card enrollment, the clinical note needs specific elements. Vague documentation delays approvals.

The note should include: confirmed hypothyroidism diagnosis (ICD-10 E03.9 or the appropriate subcategory), documented TSH values on standard tablet levothyroxine showing persistent elevation or erratic values despite verified adherence, the specific clinical reason the gel capsule formulation is necessary (malabsorption disorder, GI surgery, lactose intolerance, or other), and the prescriber's attestation that standard tablet formulations are inadequate for this patient [9].

For PA requests to Louisiana Medicaid, attaching lab results covering at least two TSH measurements while the patient was on tablet levothyroxine at an appropriate dose strengthens the case substantially. The Louisiana Medicaid PA form for non-preferred drugs requires documentation of a therapeutic failure, not merely a preference for an alternative formulation [8].

Thyroid cancer patients on suppressive therapy have additional documentation needs. Their TSH target is intentionally sub-normal, and that clinical context must be stated explicitly so the reviewer does not interpret a low TSH as overmedication [19].

Practical Steps for Louisiana Patients in 2026

Check your formulary first. Log into your insurance portal or call member services and confirm Tirosint's tier and copay before the prescription is written. If it is Tier 4 or excluded, ask your prescriber to initiate a formulary exception at the same time as the prescription.

If you are on Louisiana Medicaid, discuss the PA pathway with your provider. If the PA is denied, ask about 503A compounding as an alternative. Confirm the pharmacy holds a current Louisiana compounding permit before paying.

If you are uninsured or the cash price is unmanageable, visit the IBSA savings program page and enroll before your first fill. For patients who are ineligible for the savings card (Medicare, Medicaid), the compounded option at $0, $60 per month represents a cost difference of up to $230 per month compared to retail Tirosint [13].

Recheck TSH at 6 to 8 weeks after any formulation switch. Do not rely on symptom improvement alone to confirm that the gel capsule or compounded preparation is delivering the correct dose. TSH is the primary biochemical endpoint [6].

A 2020 study in the Journal of Thyroid Research (N=317) found that 41% of patients who switched from brand to compounded levothyroxine without subsequent TSH monitoring had TSH values outside the therapeutic range at 90 days [23]. That number dropped to 12% in the cohort with scheduled 6-week follow-up, confirming that monitoring protocol matters as much as formulation choice.